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We report a 67-year-old man with metastatic papillary renal cell 
carcinoma in whom bloody sputum developed after administration of sunitinib. 
Chest computed tomography revealed diffuse ground-glass opacity lesions, and 
bloody bronchoalveolar lavage fluid was obtained by flexible bronchoscopy. The 
abnormal shadows promptly regressed after withdrawal of sunitinib. In four 
cycles of sunitinib treatment, he suffered from controllable diffuse alveolar 
hemorrhage. Finally, he died of respiratory failure eight months after onset. 
This is the first case report of diffuse alveolar hemorrhage as an adverse 
effect of sunitinib in metastatic papillary RCC. Care should be taken with 
pulmonary hemorrhage in the use of anti-angiogenesis agents in not only 
squamous cell lung cancer but also metastatic lung tumors. 
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Renal cell carcinoma (RCC) is the most common kidney tumor, and the 
incidence has been increasing over the last several decades (1). Although 
almost histological type of RCC is clear cell carcinoma, papillary carcinoma 
occupies 7% to 14% of RCC (2). Treatment of advanced RCC with cytokines, 
such as interferon- and interleukin-2, had been standard practice for a number 
of years (3). Although the median survival period of patients with metastatic 
papillary RCC was reported as only 5.5 months and no patients survived beyond 
2 years (4), a recent study indicated a 5-year survival rate of papillary RCC of 
10% (5). Thus, the prognosis was improved because novel molecular 
therapeutic agents had demonstrated significant clinical activity in advanced 
RCC and altered the standard therapy in this disease. Of these therapies, 
sunitinib, a new oral multitargeted receptor tyrosine kinase inhibitor (TKI), is 
promising in the treatment of RCC patients. In phase III trial, progression-free 
survival was longer and response rate was higher in patients with untreated 
metastatic RCC who received sunitinib than in those receiving interferon- as 
conventional therapy (6). The patients with papillary RCC treated with sunitinib 
had prolonged median progression-free survival of 11.9 months, although overall 
clinical responses remained low (7). On the other hand, this agent shows a 
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broad range of adverse effects 3 to 4 weeks after initiation of treatment, such as 
neutropenia, thrombocytopenia, asthenia, hypertension, and bullous skin toxicity. 
However, pulmonary bleeding as an adverse effect has been seldom reported.  
Here, we report a case of metastatic papillary RCC complicated with diffuse 





At the age of 67 years, the patient complained of non-productive cough 
in June 2008 and was subsequently hospitalized in July 2008. 
He was a non-smoker. Although he had no family history of cancer, he had a 
history of tuberculous epididymitis at the age of 20, and was treated with oral 
therapy for diabetes mellitus and hypertension. The patient’s blood cell counts 
were as follows (normal ranges are shown in parentheses): hemoglobin, 12.1 
g/dL (13.5 – 17.0 g/dL); hematocrit, 36.1% (39.7% – 51.0%); white blood cells, 
7920/mm3 (3,300 – 8,800/mm3); and platelets, 373,000/mm3 (130,000 – 
350,000/mm3). The results of renal function, coagulation, and collagen studies, 
such as myeloperoxidase – anti-neutrophil cytoplasmic antibody (MPO – ANCA), 
were normal. Whole-body computed tomography (CT) revealed a huge left renal 
tumor with multiple lung and liver nodules, and mediastinal lymph node swelling. 
In addition, positron emission tomography (PET) demonstrated accumulating 
spots in multiple bone tumor lesions. Pathological diagnosis using renal and 
pulmonary CT-guided needle biopsies showed type 1 papillary RCC with lung 
metastases. The clinical stage was determined as T3bN0M1 (primary left renal 
tumor with lung, bone, liver, and mediastinal lymph node metastases) in TNM 
classification in August 2008. 
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On admission, his performance status was 1, but he suffered systemic 
metastases and the tumor growth progressed rapidly. Tumor doubling time was 
42 days. Therefore, he was spared cytoreductive nephrectomy for standard 
therapy and treated with sunitinib, a novel angiogenic inhibitor, as first-line 
systemic therapy on September, 2008. Daily treatment with sunitinib showed 
efficacy with progression control in targeting primary and multiple lung and liver 
metastatic lesions. However, he suffered a small amount of bloody sputum 
(grade 1; Common Terminology Criteria for Adverse Events ver. 3.0) on day 5 
and slight malaise (grade1) on day 7. Administration of sunitinib was then 
interrupted because thrombocytopenia (grade 3) developed on day 18. On the 
same day, the chest CT scan revealed diffuse ground-glass opacity lesions 
around lung metastatic nodular shadows (Figure 1-A). To investigate the 
abnormal shadows, flexible bronchoscopy was performed and obtained serous 
bloody bronchoalveolar lavage fluid was obtained from the superior lingular 
segment (Figure 2). After stopping sunitinib, he was treated with carbazochrome 
sodium sulfonate hydrate 100 mg against diffuse alveolar hemorrhage, resulting 
in marked reduction of the lesions determined by CT on day 40 (Figure 1-B). 
Although he was treated with interferon- after cessation of sunitinib, tumor 
growth indicated a rapidly progressive course. Then, he received four cycles of 
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sunitinib, until diffuse alveolar hemorrhage (grade 2) or thrombocytopenia (grade 
3) was observed. In four cycles of sunitinib, controllable diffuse alveolar 
hemorrhage developed as well as first administration. Finally, the patient died of 
respiratory failure eight months after the onset, due to the progression of multiple 
lung and mediastinal lymph node metastases, and pleuritis carcinomatosa and 
lymphangitic carcinomatosis. 
In the lung autopsy, diffuse peripheral alveolar hemorrhage was confirmed 
around the lung metastases (Figure 3-A). To investigate the mechanism of 
diffuse alveolar hemorrhage by sunitinib, immunohistochemistry was performed 
for VEGF in the autopsy specimens of both lung tumors and primary renal tumor 
in addition to renal biopsy specimens. Although about 60% of tumor cells 
demonstrated weak cytoplasmic staining for VEGF in renal biopsy, almost all 
tumor cells showed strong staining in both lung metastases and primary renal 





Here, we report the first case of diffuse alveolar hemorrhage as an 
adverse effect of sunitinib in metastatic papillary RCC. Sunitinib is an oral 
multitargeted TKI against VEGFR1 and 2, platelet-derived growth factor (PDGF) 
receptors  and , c-KIT, FLIT-3, and ret protooncogene (RET). Substantial 
clinical activity of sunitinib has been demonstrated in imatinib-resistant 
gastrointestinal stromal tumors, breast cancer, and other tumors (8). Similar to 
other cancers, sunitinib has a major clinical impact for RCC.  
Recently, pulmonary bleeding has been reported as an adverse effect 
with the development of antiangiogenic therapeutic approaches. Bevacizumab, 
a recombinant humanized monoclonal antibody that binds to VEGF, showed an 
adverse effect with fatal tumor-related bleeding, especially centrally located lung 
tumor or squamous cell histology, in patients enrolled in a randomized study for 
non-small cell lung carcinoma (9). Sunitinib led to fatal pulmonary bleeding 
events in two patients with advanced squamous cell lung cancer in a phase II 
trial of previously treated advanced non-small cell lung cancer (10). Therefore, 
ongoing trials for antiangiogenic agents tend to eliminate patients with 
squamous cell lung cancer. Furthermore, a retrospective study suggested that 
baseline tumor cavitation may be a potential risk factor for pulmonary 
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hemorrhage in first-line advanced non-small cell lung cancer treatment with 
carboplatin and paclitaxel plus bevacizumab (11).  
The present case represents a timely warning regarding the clinical use 
of sunitinib for some reasons as follows: 1) histological diagnosis was metastatic 
lung adenocarcinoma from RCC, but not squamous cell lung cancer, in which 
sunitinib-related diffuse alveolar bleeding has been reported; 2) lung metastatic 
tumors with hemorrhage were located in the peripheral side without cavitations; 
3) the frequency of the use of sunitinib would be anticipated to increase in the 
future. Therefore, care should be taken with regard to the adverse effects of 
sunitinib in cases of RCC lung metastases. However, the mechanism and clinical 
condition of sunitinib-associated pulmonary hemorrhage remain unclear. 
VEGF is one of the principal proangiogenic factors in solid tumors and 
plays a pivotal role in vascular development, stimulating both angiogenesis and 
vasculogenesis (12, 13). Papillary RCC tumors also show high levels of VEGF 
immunoreactivity (14) and elevated VEGF mRNA levels in papillary RCC tumors 
were associated with short survival (15). In addition, this growth factor is known 
as both a proangiogenic and survival factor for endothelial cells. Inhibition of 
VEGF results in inhibition of vascular development and significant alteration of 
epithelial development, suggesting that VEGF coordinates proper development 
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of the normal lung epithelium and vasculature (16). Therefore, it seems possible 
that inhibition of VEGF may decrease the regenerative capacity of the 
endothelial cells, resulting in endothelial dysfunction in the supporting layers of 
the blood vessels (17).  
In the present case, we speculated that the correlation with high-level 
production of VEGF from the tumor and anti-VEGF effect of sunitinib in the lung 
metastatic microenvironment may cause diffuse alveolar hemorrhage as 
adverse events, because tumor cells showed stronger expression of VEGF in 
both the primary site and the lung metastases at autopsy. On the other hand, 
Kontovinis et al. reported that plasma VEGF-A levels increased after treatment 
with sunitinib in clear-cell metastatic renal cell carcinoma (18). Therefore, we 
cannot rule out the possibility that anti-VEGF treatment itself might have induced 
the increased expression of VEGF in the autopsy specimens. In addition, 
pulmonary bleeding as an adverse effect of sunitinib has been reported only 
rarely in papillary RCC tumors. As we did not investigate other sunitinib-targeting 
molecules, such as PDGF, c-KIT, FLIT-3, and RET, further investigations 
regarding the mechanism of pulmonary hemorrhage are required.  
In conclusion, we reported a case of metastatic papillary RCC with 
controllable diffuse alveolar hemorrhage as an adverse event associated with 
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sunitinib. Care should be taken with pulmonary hemorrhage in the use of 
anti-angiogenesis agents in not only squamous cell lung cancer but also 
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Chest computed tomography revealing diffuse ground-glass opacity lesions 
around lung metastases on day 18 after treatment with sunitinib (Fig. 1-A). The 
lesions disappeared on day 40 (Fig. 1-B). 
 
Figure 2 
Flexible bronchoscopy demonstrating bronchial hemorrhage from the superior 
lingular segment (Fig. 2-A). Serous blood in bronchoalveolar lavage fluid was 
observed (Fig. 2-B). 
 
Figure 3 
Histological findings of peripheral alveolar hemorrhage around lung metastases 
at autopsy (Fig. 3-A). Immunohistochemical findings showing strongly positive 
cytoplasmic staining for VEGF in lung metastases at autopsy (Fig. 3-B). A, H&E, 
×200; B, Immunostaining of VEGF, ×200. 
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